Home › Cancro dell'endometrio › Rhode Island › Providence
Studi clinici su Cancro dell'endometrio a Providence, RI
14 studi su Cancro dell'endometrio cercano partecipanti presso sedi a Providence e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
In reclutamentoFase 2
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
In reclutamentoFase 1
- Women and Infants Hospital, Providence
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
In reclutamentoFase 3
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
In reclutamentoFase 2
- Women and Infants Hospital, Providence
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
In reclutamentoFase 2
- Women and Infants Hospital, Providence
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
In reclutamentoFase 3
- Women & Infants Hospital ( Site 5003), Providence
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
In reclutamentoFase 1
- Women & Infants Hospital of Rhode Island, Providence
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
In reclutamentoFase 3
- Research Site, Providence
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
In reclutamentoFase 1/2
- Research Site, Providence
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
In reclutamentoFase 2
- Women & Infants Hospital, Providence
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
In reclutamentoFase 1/2
- Women and Infants Hospital of Rhode Island, Providence
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
In reclutamentoFase 2
- Women & Infants Hospital, Providence
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
In reclutamentoFase 1/2
- Women & Infants Hospital, Providence
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Providence
Studi su Cancro dell'endometrio in altre città
- Houston, TX68 studi
- New York City, NY52 studi
- Boston, MA50 studi
- Arlington, VA39 studi
- Nashville, TN38 studi
- Los Angeles, CA34 studi
- St. Louis, MO29 studi
- Philadelphia, PA28 studi
- San Antonio, TX27 studi
- Queens, NY25 studi
- Columbus, OH25 studi
- Chicago, IL25 studi
Altri studi a Providence
- Cancro ovarico15 studi
- Obesità14 studi
- Cancro del polmone non a piccole cellule12 studi
- Cancro (tutti i tipi)12 studi
- Malattia di Crohn12 studi
- Colite ulcerosa11 studi
- Cancro al seno11 studi
- Leucemia mieloide acuta10 studi
- Cancro metastatico9 studi
- Sovrappeso9 studi
- Morbo di Alzheimer8 studi
- Disturbo da uso di alcol (AUD)8 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.